Home › Alpha-1 Antitrypsin Deficiency › Florida › Miami
Alpha-1 Antitrypsin Deficiency clinical trials in Miami, FL
3 studies for Alpha-1 Antitrypsin Deficiency are looking for participants at sites in and around Miami (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
RecruitingPhase 3
- GC2501 Study Site 105, Miami
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
RecruitingPhase 3
- Schiff Center for Liver Diseases/University of Miami, Miami
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
RecruitingPhase 3
- Schiff Center for Liver Diseases/University of Miami, Miami
About Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency is an inherited condition that raises your risk for lung and liver disease. Learn about the symptoms and treatment.
More about Alpha-1 Antitrypsin Deficiency on MedlinePlus
Alpha-1 Antitrypsin Deficiency trials in other cities
- Gainesville, FL6 studies
- Charleston, SC6 studies
- Birmingham, AL5 studies
- New York City, NY4 studies
- Boston, MA4 studies
- Rochester, MN4 studies
- Cleveland, OH3 studies
- Phoenix, AZ3 studies
- Los Angeles, CA3 studies
Other studies in Miami
- Breast Cancer42 studies
- Cancer (all types)36 studies
- Non-Small Cell Lung Cancer31 studies
- Prostate Cancer27 studies
- Obesity27 studies
- Acute Myeloid Leukemia24 studies
- Metastatic Cancer24 studies
- Ovarian Cancer23 studies
- Overweight23 studies
- Multiple Myeloma21 studies
- Ulcerative Colitis21 studies
- Alzheimer's Disease20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.